By now we all know how Medtronic knocked Johnson & Johnson JNJ from its indisputable position as the top firm in the medical devices space, thanks to the $43 billion Covidien merger last year. It’s really amazing to see how a single mega consolidation reshuffled the dynamics of the entire medical devices space.
And after that the industry hasn’t taken a breather. Deals like Zimmer-Biomet ZBH, Johnson & Johnson -Synthes and Thermo Fisher-Life Technologies and many more gave birth to unprecedented leaders in their respective niche markets. A number of untoward factors in the global economy over the past one and a half years did nothing to stop the pace of these consolidations.
In fact, going by the last available EvaluateGroup data, the first half of 2015 saw 86 mergers and acquisitions, totaling $83 billion, a rise of 166% from the year-ago period. Although the next report is not yet released, the unofficial talk is that the full year target of $100 billion of M&A valuation was effortlessly reached with the legacy continuing into 2016.